Track record · closed signal

Abbott Laboratories (ABT) — closed signal from April 28, 2026

Near target Published before the outcome was known, scored automatically when the window closed on July 27, 2026 — +11.6% at the close.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted

$90.21 – $94.15Entry zone — fair-value band

$93.65Published — price the day we called it

$106.94Target — the price the thesis aimed for

$105.86Peak — highest point inside the window, not a realized return

$104.49Window close — end-of-window price, context only

What happened

Near target

Came within reach: 87% of the predicted growth at its peak, just short of the target.

At window close

+11.6%

realized, from the publication price to the last close inside the window

Peak gain

+13%

peak, from the publication price — not a realized return

S&P 500, same window

+4.1%

SPY over the identical days, dividend-adjusted

Window close

$104.49

last close inside the window, ended July 27, 2026

Peak price

$105.86

peak on July 27, 2026 — not a realized return

Days to target

—

The thesis — published April 28, 2026

Predicted growth

+15%

over the measurement window

Target price

$106.94

the price the thesis aimed for

Entry zone

$90.21 – $94.15

the fair-value band we waited for

Price at publication

$93.65

published April 28, 2026

Confidence

74%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Abbott looks like a steady healthcare company that could bounce rather than a fast-growing stock. Recent approvals for its coronary imaging product and positive device data give real reasons to expect product-driven improvement. A recent analyst downgrade and weaker sales growth keep confidence moderate, while the company's defensive mix helps limit big swings.

Primary drivers

Regulatory approvals for the coronary imaging product that support sales
New device data improves the long-term product lineup and prospects
Business mix leans to stable healthcare products that reduce volatility
Recent pullback makes this a less popular but clearer recovery setup

How it played out

ABT: 13% gain, target missed

Lyra published ABT at $93.65 with 15% expected growth. The thesis called for a steady healthcare recovery rather than rapid growth. It pointed to regulatory approvals for coronary imaging, new device data, a stable business mix, and a recent pullback. It also noted weaker sales growth and an analyst downgrade, which kept confidence at 74%.

ABT rose to a $105.86 peak on July 27, a 13% gain, but it never reached the $106.94 target. It ended the window at $104.49. The price moved close to the published target and held most of its peak gain, but the full 15% thesis did not play out. The thesis partially played out.

What happened during the window

On May 27, Abbott said it had secured CE Mark for its Libre Duo glucose and ketone sensor. On July 16, Abbott reported second-quarter sales of $12.6 billion and adjusted diluted earnings per share of $1.31.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals